<DOC>
	<DOCNO>NCT01649258</DOCNO>
	<brief_summary>This clinical trial study well fosaprepitant dimeglumine granisetron transdermal system work prevent nausea vomit patient breast cancer undergo chemotherapy . Antiemetic drug may help lessen prevent nausea vomit patient treat chemotherapy</brief_summary>
	<brief_title>Fosaprepitant Dimeglumine Granisetron Transdermal System Preventing Nausea Vomiting Patients With Breast Cancer Undergoing Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To evaluate efficacy combination fosaprepitant ( fosaprepitant dimeglumine ) granisetron transdermal system prevention acute delay chemotherapy induced nausea vomit breast cancer patient undergo adjuvant neoadjuvant chemotherapy . SECONDARY OBJECTIVE : I . To evaluate safety combination fosaprepitant granisetron transdermal system breast cancer patient undergo adjuvan neoadjuvant chemotherapy . EXPLORATORY OBJECTIVE : I . To explore use single nucleotide polymorphism ( SNPs ) 5Ã¢hydroxytryptamine-3 ( 5HT3 ) neurokinin-1 ( NK-1 ) receptors potential marker efficacy . OUTLINE : Patients receive granisetron transdermal system patch 24-48 hr initiation chemotherapy . Patients wear granisetron transdermal system patch 7 day . Patients receive fosaprepitant dimeglumine intravenously ( IV ) 15 minute day 1 chemotherapy . Treatment repeat every 2 3 week 4 course absence unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<criteria>Patients histologically confirm breast cancer schedule receive chemotherapy doxorubicin cyclophosphamide ( adjuvant neoadjuvant ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Projected life expectancy least 3 month Provision inform consent prior studyrelated procedure Negative pregnancy test woman childbearing potential Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 100,000 cells/mm^3 Hemoglobin &gt; = 9.0g/dL Serum creatinine = &lt; 1.5 mg/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 X upper limit normal ( ULN ) Alkaline phosphatase = &lt; 2.5 X upper limit normal ; patient bone metastasis evidence liver metastasis bilirubin = &lt; upper limit normal alkaline phosphatase = &lt; 5 ULN allow Serum bilirubin = &lt; 1.0 mg/dL No concomitant therapy direct cancer allow Allergy intolerance 5HT3 NK1 antagonist dexamethasone Use another antiemetic agent ( 5HT3 antagonist , phenothiazine , butyrophenones , cannabinoids , metoclopramide , corticosteroid ) within 72 hour prior day 1 study Use anticoagulant agent ( Warfarin , Coumadin , Jantoven , Marevan , Lawarin , Waran , Warfant ) An episode vomit retch within 24 hour start initial treatment chemotherapy Severe concurrent illness neoplasia Gastrointestinal obstruction active peptic ulcer Patients pregnant breast feeding aprepitant may harmful develop fetus newborn</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>